ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
08 mars 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief...
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
01 mars 2021 16h05 HE
|
ChemoCentryx, Inc.
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in...
ChemoCentryx to Present at Two Upcoming Investor Conferences
25 févr. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
24 févr. 2021 08h30 HE
|
ChemoCentryx, Inc.
-- Brings more than two decades of executive management experience from global pharmaceutical companies -- MOUNTAIN VIEW, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:...
ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
23 févr. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released...
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
17 févr. 2021 17h00 HE
|
ChemoCentryx, Inc.
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s...
ChemoCentryx to Participate in Two Upcoming Investor Conferences
06 janv. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
21 déc. 2020 16h05 HE
|
ChemoCentryx, Inc.
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatmentThe change from baseline...
ChemoCentryx to Present at Two Upcoming Investor Conferences
19 nov. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
09 nov. 2020 16h05 HE
|
ChemoCentryx, Inc.
-- New Drug Application (NDA) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA-associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing...